Phase I trial of RG 012 as a potential therapy for Alport syndrome.

Trial Profile

Phase I trial of RG 012 as a potential therapy for Alport syndrome.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs RG 012 (Primary)
  • Indications Nephritis
  • Focus Adverse reactions; First in man
  • Sponsors Regulus Therapeutics
  • Most Recent Events

    • 05 Nov 2015 Status changed from recruiting to completed, according to a Regulus Therapeutics media release.
    • 04 Aug 2015 Results are expected to be reported in the second half of 2015, according to a Regulus Therapeutics media release.
    • 04 Jun 2015 Status changed from planning to recruiting according to a Regulus Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top